Skip to main content
×
×
Home

Risperidone in the Treatment of Patients with Chronic Schizophrenia: a Multi-National, Multi-Centre, Double-Blind, Parallel-Group Study versus Haloperidol

  • J. Peuskens
Abstract
Background

This study was performed in order to evaluate the short-term efficacy and safety of fixed risperidone doses compared to haloperidol.

Method

In a multi-national, parallel-group, double-blind study, patients with chronic schizophrenia (DSM–III–R) were randomly assigned to risperidone 1, 4, 8, 12 or 16 mg or haloperidol 10 mg daily for 8 weeks. Efficacy was assessed by the Positive and Negative Syndrome Scale for schizophrenia (PANSS) and clinical global impression (CGI), and safety primarily by the Extrapyramidal Symptom Rating Scale (ESRS).

Results

One thousand three hundred and sixty-two patients were evaluated. The optimum risperidone doses were 4 mg and 8 mg, with response rates of 63.4% (56.8%; 69.7%) and 65.8% (59.2%; 71.9%) respectively. Response rate in haloperidol-treated patients was 58.7% (52.0%; 65.3%); the 95% confidence intervals (CI) of the differences between risperidone 4 mg or 8 mg and haloperidol were (–4.3%; 13.7%) and (–1.9%; 16.0%) respectively. There were no significant differences in CGI scores at endpoint between risperidone 4 mg, 8 mg, 12 mg and 16 mg and haloperidol (3.0, 3.0, 3.2, 3.1 and 3.1 respectively); the 95% CI of the differences between risperidone 4 mg or 8 mg and haloperidol were (–0.4; 0.1) and (–0.3; 0.2) respectively. Mean shifts to the maximum total ESRS scores versus baseline (mean (confidence interval)) were significantly greater in haloperidol-treated patients (5.1 (4.0; 6.2)) than in the risperidone 1, 4, 8 and 12 mg groups (1.1 (0.3; 1.9); 1.8 (0.9; 2.7); 2.7 (1.8; 3.6) and 3.2 (2.3; 4.1) respectively (P< 0.05)).

Conclusion

Risperidone is an effective antipsychotic for the treatment of chronic schizophrenia; doses of 4 and 8 mg seem to be optimal and have a lower incidence of side-effects than haloperidol.

Copyright
Corresponding author
Professor J. Peuskens, Universitair Centrum St Jozef, Leuvense Steenweg 517, 3070 Kortenberg, Belgium.
References
Hide All
American Psychiatric Association (1987) Diagnostic and Statistical Manual of Mental Disorders (3rd edn, revised) (DSM–III–R). Washington, DC: APA.
Baldessarini, R. J., Cohen, B. M., Teicher, M. H. (1988) Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Archives of General Psychiatry, 45, 7991.
Barnes, T. R. E. (1987) The present status of tardive dyskinesia and akathisia in the treatment of schizophrenia. Psychiatric Developments, 4, 301319.
Bersani, G., Bressa, G. M., Meco, G., et al (1990) Combined serotonin 5-HT2 and dopamine-D2 antagonism in schizophrenia: clinical, extrapyramidal and neuroendocrine response in a preliminary study with risperidone (R64766). Human Psychopharmacology, 5, 225231.
Borison, R. L., Pathiraja, A. P., Diamond, B. I., et al (1992) Risperidone: Clinical safety and efficacy in schizophrenia. Psychopharmacology Bulletin 28(2), 213218.
Castelao, J. F., Ferreira, L., Gelders, Y. G., et al (1989) The efficacy of the D2 and 5-HT2 antagonist risperidone (R64766) in the treatment of chronic psychosis: an open dose-finding study. Schizophrenia Bulletin, 2, 411415.
Ceulemans, D. L. S., Gelders, Y. G., Hoppenbrouwers, M-L. J. A., et al (1985) Effect of serotonin antagonism in schizophrenia: a pilot study with setoperone. Psychopharmacology, 85, 329332.
Chouinard, G., Annable, L., Ross-Chouinard, A., et al (1979) Ethopropazine and benztropine in neuroleptic-induced Parkinsonism. Journal of Clinical Psychiatry, 40, 147152.
Chouinard, G., Jones, B., Remington, G., et al (1993) A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Journal of Clinical Psychopharmacology, 13, 2540.
Chouinard, G., Ross-Chouinard, A., Annable, L., et al (1980) The Extrapyramidal Symptom Rating Scale. Canadian Journal of Neurological Sciences, 7, 233.
Claus, A., Bollen, J., De Cuyper, H., et al (1992) Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicenter double-blind comparative study. Acta Psychiatrica Scandinavica, 85, 295305.
Crow, T. J. (1985) The two-syndrome concept: origins and status. Schizophrenia Bulletin, 11, 471486.
Drake, R. E. & Ehrlich, J. (1985) Suicide attempts associated with akathisia. American Journal of Psychiatry, 142, 499501.
Farde, L., Hall, H. (1992) Positron emission tomography. Examination of chemical transmission in the living human brain. Arzneim-Forsch/Drug Research, 42, 260264.
Gelders, Y. G. (1989) Thymosthenic agents, a novel approach in the treatment of schizophrenia. British Journal of Psychiatry, 155(suppl 5), 3336.
Gelders, Y. G., Heylen, S. L. E., Vanden Bussche, G., et al (1990) Pilot clinical investigations of risperidone in the treatment of psychotic patients. Pharmacopsychiatry, 23, 206211.
Guy, W. (1976) ECDEU Assessment Manual for Psychopharmacology (revised). Published by DHEW, No (ADM) 76–338, Rockville, MD: National Institute of Mental Health.
Janssen, P. A. J., Niemegeers, C. J. E., Awouters, F., et al (1988) Pharmacology of risperidone (R64766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. Journal of Pharmacological Experimental Therapeutics, 244, 685693.
Kalinowski, L. B. (1958) Appraisal of the “tranquillisers” and their influences on other somatic treatment in psychiatry. American Journal of Psychiatry, 115, 94300.
Kay, S. R., Fiszbein, A. & Opler, L. A. (1987) The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia. Schizophrenia Bulletin, 13, 261276.
Kay, S. R., Opler, L. A. & Lindenmayer, J. P. (1988) Reliability and validity of the Positive and Negative Syndrome Scale for Schizophrenics. Psychiatric Research, 23, 99110.
Kay, S. R. & Sevy, S. (1990) Pyramidical model of schizophrenia. Schizophrenia Bulletin, 16, 537545.
Lehmann, E. L. (1975) Nonparametric Statistical Methods, Statistical Methods based on Ranks. San Francisco: Holden-Day.
Leysen, J. E., Gommeren, W., Eens, A., et al (1988) The biochemical profile of risperidone, a new antipsychotic. Journal of Pharmacological Experimental Therapeutics, 247, 661670.
Lingjaerde, O., Ahlfors, U. G., Bech, P., et al (1987) The UKU Side-Effect Rating Scale. Acta Psychiatrica Scandinavica, 76(suppl 334), 8194.
Marder, S. R., Meibach, R. C. (1994) Risperidone in the treatment of schizophrenia. American Journal of Psychiatry, 151, 18251835.
Meco, G., Bedini, L., Bonifati, V., et al (1989) Risperidone in the treatment of chronic schizophrenia with tardive dyskinesia: a single-blind crossover study versus placebo. Current Therapeutic Research, 46, 876883.
Mesotten, F., Suy, E., Pietquin, M., et al (1989) Therapeutic effect and safety of increasing doses of risperidone (R64766) in psychotic patients. Psychopharmacology, 99, 445449.
Nordström, A. L., Farde, L., Halldin, C. (1992) Time course of D2-dopamine receptor occupancy examined by PET after single oral doses of haloperidol. Psychopharmacology, 106, 433438.
Overall, J. F. & Gorham, D. R. (1962) The Brief Psychiatric Rating Scale. Psychological Reports, 10, 799812.
Pocock, S. J. (1983) Methods of randomisation: Preparing the randomisation list. In Clinical Trials. A Practical Approach, pp 7380. Chichester: John Wiley & Sons.
Reyntjens, A. J. M., Gelders, Y. G., Hoppenbrouwers, M.-L. J. A., et al (1986) Thymosthenic effects of ritanserin (R55667), a centrally acting serotonin-S2 receptor blocker. Drug Development and Research, 8, 205211.
Shear, K., Frances, A. & Weiden, P. (1983) Suicide associated with akathisia and depot fluphenazine treatment. Journal of Clinical Psychopharmacology, 3, 235236.
Turri, M., Stein, G. (1986) The determination of practically useful doses of new drugs: some methodological considerations. Statistics in Medicine, 5, 449457.
Van Putten, T. (1974) Why do schizophrenic patients refuse to take their drugs? Archives of General Psychiatry, 31, 6772.
Van Putten, T. (1984) Akathisia with haloperidol and thiothixene. Archives of General Psychiatry, 41, 10361039.
Van Putten, T. & Marder, S. R. (1987) Behavioral toxicity of antipsychotic drugs. Journal of Clinical Psychiatry, 48(suppl 9), 1319.
Van Putten, T., Marder, S. R. & Mintz, J. (1990) A controlled dose comparison of haloperidol in newly admitted schizophrenic patients. Archives of General Psychiatry, 47, 754758.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

The British Journal of Psychiatry
  • ISSN: 0007-1250
  • EISSN: 1472-1465
  • URL: /core/journals/the-british-journal-of-psychiatry
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 55 *
Loading metrics...

Abstract views

Total abstract views: 225 *
Loading metrics...

* Views captured on Cambridge Core between 2nd January 2018 - 18th August 2018. This data will be updated every 24 hours.

Risperidone in the Treatment of Patients with Chronic Schizophrenia: a Multi-National, Multi-Centre, Double-Blind, Parallel-Group Study versus Haloperidol

  • J. Peuskens
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *